{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:30:10Z","timestamp":1792884610542,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CRD42023482439"],"award-info":[{"award-number":["CRD42023482439"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clml.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:41:21Z","timestamp":1718221281000},"page":"e376-e384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-6280","authenticated-orcid":false,"given":"Muhammad Ashar","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-8788","authenticated-orcid":false,"given":"Wajeeha","family":"Aiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2024.06.002_bib0001","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.hoc.2009.07.001","article-title":"Cytogenetics and molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Mr\u00f3zek","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.clml.2024.06.002_bib0002","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","article-title":"Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms","volume":"35","author":"Short","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.06.002_bib0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.002_bib0004","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2024.06.002_bib0005","first-page":"23","article-title":"Blinatumomab for the treatment of adult B-cell acute lymphoblastic leukemia: toward a new era of targeted immunotherapy","volume":"14","author":"Franquiz","year":"2020","journal-title":"Biologics"},{"key":"10.1016\/j.clml.2024.06.002_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"System Rev"},{"key":"10.1016\/j.clml.2024.06.002_bib0007","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. 2008;","DOI":"10.1002\/9780470712184"},{"issue":"6","key":"10.1016\/j.clml.2024.06.002_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emerg Med J"},{"issue":"4","key":"10.1016\/j.clml.2024.06.002_bib0009","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.002_bib0010","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"issue":"1","key":"10.1016\/j.clml.2024.06.002_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I(2) is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.clml.2024.06.002_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/1355819021927674","article-title":"Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice","volume":"7","author":"Higgins","year":"2002","journal-title":"J Health Serv Res Policy"},{"issue":"4","key":"10.1016\/j.clml.2024.06.002_bib0013","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/3001616","article-title":"Some Methods for Strengthening the Common \u03c7 2 Tests","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.clml.2024.06.002_bib0014","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.clml.2024.06.002_bib0015","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.06.002_bib0016","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.002_bib0017","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.18975","article-title":"Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial","volume":"202","author":"Xie","year":"2023","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.clml.2024.06.002_bib0018","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.06.002_bib0019","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.06.002_bib0020","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia. Article","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2024.06.002_bib0021","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.06.002_bib0022","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.06.002_bib0023","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.06.002_bib0024","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.002_bib0026","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Article","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.06.002_bib0027","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.clml.2024.06.002_bib0028","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cncr.33529","article-title":"Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2024.06.002_bib0029","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","article-title":"A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.clml.2024.06.002_bib0030","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.06.002_bib0031","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2024.06.002_bib0033","first-page":"155","article-title":"Inotuzumab ozogamicin with bosutinib in relapsed or refractory philadelphia chromosomepositive (ph+) acute lymphoblastic leukemia (ALL) or chronic myeloid leukemia in lymphoid blast phase (CML-LBP)","volume":"4","author":"Jain","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2024.06.002_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-134390","article-title":"Interim results of the phase I\/II study of the ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"136","author":"Short","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:27Z","timestamp":1778838567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2152265024002301"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}